HUP0000567A2 - Szulfonil-karbamid-származékok és ezeket tartalmazó interleukin-1 aktivitás gátlására szolgáló gyógyászati készítmények - Google Patents
Szulfonil-karbamid-származékok és ezeket tartalmazó interleukin-1 aktivitás gátlására szolgáló gyógyászati készítményekInfo
- Publication number
- HUP0000567A2 HUP0000567A2 HU0000567A HUP0000567A HUP0000567A2 HU P0000567 A2 HUP0000567 A2 HU P0000567A2 HU 0000567 A HU0000567 A HU 0000567A HU P0000567 A HUP0000567 A HU P0000567A HU P0000567 A2 HUP0000567 A2 HU P0000567A2
- Authority
- HU
- Hungary
- Prior art keywords
- substituents
- general formula
- activity
- independently
- compounds
- Prior art date
Links
- 102000000589 Interleukin-1 Human genes 0.000 title abstract 2
- 108010002352 Interleukin-1 Proteins 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 201000009906 Meningitis Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 208000038016 acute inflammation Diseases 0.000 abstract 1
- 230000006022 acute inflammation Effects 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 230000006020 chronic inflammation Effects 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010014599 encephalitis Diseases 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
A találmány tárgyát az (I) általános képletű vegyületek és ezekgyógyászatilag megfelelő sói képezik; a találmány tárgyához tartoznakezenkívül e vegyületeket tartalmazó gyógyászati készítmények is. Atalálmány szerinti szulfonil-karbamid-származékok eredményesenalkalmazhatók az interleukin-1 aktivitásának csökkentésére és mintilyenek, számos betegség kezelésére adhatók, ezen betegségek közülemlítjük meg például az agyhártyagyulladást, a méhkürtgyulladást, aszeptikus sokkot, a légzőszervi zavar szindrómáját, az akut éskrónikus gyulladásokat, izületi gyulladást, agyvelőgyulladást, az 1-estípusú diabetes mellitus-t, sclerosis multiplex-et, Alzheimer-félebetegséget, depressziót atherosclerosis-t és osteoporosis-t. Az (I)általános képletben a szubsztituensek jelentése igen sokféle, ígypéldául R1 jelentése adott esetben szubsztituált 1-6 szénatomos alkilcsoport,aril-, cikloalkil- vagy egyéb, igen sokféle szubsztituens, vagy R1 és R2 egymástól függetlenül jelenthet egy (II) általános képletűcsoportot, amelyben a szaggatott vonal egy adott esetben jelenlévő kettős kötést jelent, n értéke 0, 1, 2 vagy 3, és A, B, D, E és G jelentése egymástól függetlenül oxigénatom, kénatom,nitrogénatom vagy CR5R6 általános képletű csoport, amelyben R5 és R6 jelentése egymástól függetlenül vagy együttesen igen sokfélecsoport, így hidrogénatom, 1-6 szénatomos alkilcsoport, amely sokféleszubsztituenst hordozhat. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3697997P | 1997-01-29 | 1997-01-29 | |
| PCT/IB1997/001603 WO1998032733A1 (en) | 1997-01-29 | 1997-12-29 | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0000567A2 true HUP0000567A2 (hu) | 2000-10-28 |
| HUP0000567A3 HUP0000567A3 (en) | 2002-10-28 |
Family
ID=21891776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0000567A HUP0000567A3 (en) | 1997-01-29 | 1997-12-29 | Sulfonyl urea derivatives and pharmaceutical compositions thereof inhibiting interleukin-1 activity |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US6166064A (hu) |
| EP (1) | EP0964849B1 (hu) |
| JP (1) | JP3573757B2 (hu) |
| KR (1) | KR100324058B1 (hu) |
| CN (1) | CN1127479C (hu) |
| AP (1) | AP929A (hu) |
| AR (1) | AR011093A1 (hu) |
| AT (2) | ATE270285T1 (hu) |
| AU (1) | AU723895B2 (hu) |
| BG (1) | BG103597A (hu) |
| BR (1) | BR9714328A (hu) |
| CA (1) | CA2279186C (hu) |
| CO (1) | CO4920230A1 (hu) |
| CZ (1) | CZ293173B6 (hu) |
| DE (2) | DE69722663T2 (hu) |
| DK (2) | DK1270565T3 (hu) |
| DZ (1) | DZ2407A1 (hu) |
| EA (1) | EA001803B1 (hu) |
| ES (2) | ES2198598T3 (hu) |
| HR (1) | HRP980045B1 (hu) |
| HU (1) | HUP0000567A3 (hu) |
| ID (1) | ID22223A (hu) |
| IL (1) | IL130855A0 (hu) |
| IS (1) | IS5099A (hu) |
| MA (1) | MA26468A1 (hu) |
| NO (1) | NO313279B1 (hu) |
| NZ (1) | NZ336248A (hu) |
| OA (1) | OA11079A (hu) |
| PA (1) | PA8444701A1 (hu) |
| PE (1) | PE57898A1 (hu) |
| PL (1) | PL335052A1 (hu) |
| PT (2) | PT964849E (hu) |
| SK (1) | SK283679B6 (hu) |
| TN (1) | TNSN98017A1 (hu) |
| TR (1) | TR199901816T2 (hu) |
| TW (1) | TW515788B (hu) |
| UY (1) | UY24861A1 (hu) |
| WO (1) | WO1998032733A1 (hu) |
| YU (1) | YU33799A (hu) |
| ZA (1) | ZA98685B (hu) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6022984A (en) * | 1998-07-27 | 2000-02-08 | Pfizer Inc. | Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors |
| EP1526383A3 (en) * | 1998-08-31 | 2005-11-16 | Pfizer Products Inc. | Diarylsulfonylurea binding proteins |
| IT1303249B1 (it) * | 1998-10-23 | 2000-11-06 | Dompe Spa | Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. |
| BR0014003A (pt) * | 1999-09-14 | 2002-05-21 | Pfizer Prod Inc | Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| CA2369967A1 (en) * | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
| MEP32608A (en) | 2001-06-26 | 2011-02-10 | Amgen Fremont Inc | Antibodies to opgl |
| MXPA04001785A (es) | 2001-09-14 | 2004-07-08 | Bayer Ag | Benzofurano y derivados de dihidrobenzofurano utiles como agonistas de beta-3 adrenoreceptores. |
| EP1487457A1 (en) * | 2001-11-30 | 2004-12-22 | Pfizer Products Inc. | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation |
| US20030131370A1 (en) * | 2001-12-14 | 2003-07-10 | Pfizer Inc. | Disruption of the glutathione S-transferase-Omega-1 gene |
| JP2005538066A (ja) | 2002-07-09 | 2005-12-15 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規な抗コリン作用薬及びｐ３８キナーゼ阻害剤を用いた新規な医薬組成物 |
| ES2565189T3 (es) | 2002-09-06 | 2016-04-01 | Amgen, Inc | Anticuerpo monoclonal anti-IL-1R1 humano terapéutico |
| AU2003263560A1 (en) * | 2002-10-03 | 2004-04-23 | Pfizer Products Inc. | Use of gst-omega-2 as a therapeutic target |
| EP3431464A3 (en) | 2003-08-06 | 2019-07-31 | Senomyx Inc. | Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof |
| PT1776336E (pt) * | 2004-03-23 | 2009-12-18 | Dompe Spa | Derivados de ácido 2-fenilpropiónico e composições farmacêuticas que os contêm |
| US20060045953A1 (en) * | 2004-08-06 | 2006-03-02 | Catherine Tachdjian | Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| US8968708B2 (en) | 2005-02-04 | 2015-03-03 | Senomyx, Inc. | Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions |
| WO2006090921A1 (ja) * | 2005-02-28 | 2006-08-31 | Eisai R & D Management Co., Ltd. | スルホンアミド化合物のリンパ球活性化抑制作用 |
| US7208526B2 (en) * | 2005-05-20 | 2007-04-24 | Hoffmann-La Roche Inc. | Styrylsulfonamides |
| TW200715993A (en) | 2005-06-15 | 2007-05-01 | Senomyx Inc | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers |
| KR101387563B1 (ko) | 2006-04-21 | 2014-04-25 | 세노믹스, 인코포레이티드 | 고효능의 조미용 향료를 포함하는 식품 조성물 및 이의 제조 방법 |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| US7973051B2 (en) * | 2007-11-30 | 2011-07-05 | Hoffman-La Roche Inc. | Aminothiazoles as FBPase inhibitors for diabetes |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US10385040B2 (en) | 2014-08-12 | 2019-08-20 | Loyola University Of Chicago | Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same |
| MX2017010528A (es) | 2015-02-16 | 2018-11-12 | Univ Queensland | Sulfonilureas y compuestos relacionados y uso de estos. |
| US10688077B2 (en) * | 2015-02-26 | 2020-06-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inflammasome activation in myelodysplastic syndromes |
| FR3046933B1 (fr) | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| CA3014487A1 (en) * | 2016-02-16 | 2017-08-24 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Sulfonylureas and related compounds and use of same |
| AU2017254523B2 (en) | 2016-04-18 | 2021-09-02 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| ES2940611T3 (es) * | 2016-04-18 | 2023-05-09 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| EP3272739A1 (en) * | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| WO2018102419A1 (en) * | 2016-11-29 | 2018-06-07 | Epizyme, Inc. | Compounds containing a sulfonic group as kat inhibitors |
| AU2018210525B2 (en) | 2017-01-23 | 2022-06-02 | Genentech, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| BR112019024831A2 (pt) * | 2017-05-24 | 2020-06-09 | The University Of Queensland | composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3 |
| EP3634951B8 (en) | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| WO2019008029A1 (en) | 2017-07-07 | 2019-01-10 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| SI3661925T1 (sl) | 2017-07-07 | 2022-04-29 | Inflazome Limited | Nove sulfonamidne in karboksamidne spojine |
| KR102565167B1 (ko) | 2017-07-24 | 2023-08-11 | 노파르티스 아게 | Nlrp 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물 |
| TW201910316A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| AU2018317800A1 (en) | 2017-08-15 | 2020-02-13 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| EP3668842A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| EP3668843A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| US11518739B2 (en) | 2017-08-15 | 2022-12-06 | Inflazome Limited | Sulfonamide carboxamide compounds |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| WO2019068772A1 (en) | 2017-10-03 | 2019-04-11 | Inflazome Limited | NEW COMPOUNDS |
| ES2927851T3 (es) * | 2017-10-17 | 2022-11-11 | Novartis Ag | Sulfonamidas y composiciones de las mismas para tratar afecciones asociadas con la actividad de NLRP |
| KR20200087759A (ko) | 2017-11-09 | 2020-07-21 | 인플라좀 리미티드 | 신규한 설폰아마이드 카복스아마이드 화합물 |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| CN108299256B (zh) * | 2018-01-09 | 2019-09-10 | 武汉大学 | 一类2,3,4-三羟基苯磺酰胺衍生物及其制备方法和应用 |
| WO2019166629A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| EP3759103A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| EP3759078A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
| EP3759102A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| CN112584899A (zh) * | 2018-07-03 | 2021-03-30 | 诺华股份有限公司 | Nlrp调节剂 |
| EP3823726A1 (en) * | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche SA | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
| US20210236599A1 (en) | 2018-08-13 | 2021-08-05 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| US20230011652A1 (en) | 2018-10-24 | 2023-01-12 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| US12084416B2 (en) | 2019-01-14 | 2024-09-10 | Zydus Lifesciences Limited | Substituted sulfonylurea derivatives |
| JP2022535956A (ja) | 2019-06-12 | 2022-08-10 | ノッドセラ リミテッド | スルホニル尿素誘導体及びその使用 |
| EP3986879A1 (en) | 2019-06-21 | 2022-04-27 | AC Immune SA | Fused 1,2 thiazoles and 1,2 thiazines which act as nl3p3 modulators |
| US20220313657A1 (en) * | 2019-09-12 | 2022-10-06 | Cadila Healthcare Limited | Novel substituted sulfoximine derivatives |
| US20230219920A1 (en) * | 2020-06-11 | 2023-07-13 | Medshine Discovery Inc. | Dimethylsulfoximine derivative |
| BR112022025612A2 (pt) | 2020-06-19 | 2023-01-17 | Ac Immune Sa | Derivados de di-hidro-oxazol e tioureia modulando a via do inflamassoma nlrp3 |
| WO2022022646A1 (zh) * | 2020-07-29 | 2022-02-03 | 南京明德新药研发有限公司 | 含硒五元杂芳环化合物 |
| WO2022051582A1 (en) | 2020-09-04 | 2022-03-10 | NodThera Limited | Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof |
| ES2948511A1 (es) * | 2021-09-08 | 2023-09-13 | Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa | Derivados de n-sulfonilureas y su uso terapeutico |
| WO2023098612A1 (zh) * | 2021-12-03 | 2023-06-08 | 南京明德新药研发有限公司 | 二甲基亚磺酰亚胺衍生物的盐型及晶型 |
| WO2023118521A1 (en) | 2021-12-22 | 2023-06-29 | Ac Immune Sa | Dihydro-oxazol derivative compounds |
| WO2023156311A1 (en) * | 2022-02-15 | 2023-08-24 | F. Hoffmann-La Roche Ag | Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives |
| WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
| US20240034735A1 (en) | 2022-07-14 | 2024-02-01 | Ac Immune Sa | Novel compounds |
| US20240101563A1 (en) | 2022-07-28 | 2024-03-28 | Ac Immune Sa | Novel compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4586950A (en) * | 1982-05-31 | 1986-05-06 | E. I. Du Pont De Nemours & Company | Novel phenyl-substituted sulfonamides |
| US4780125A (en) * | 1982-09-01 | 1988-10-25 | Ciba-Geigy Corporation | N-phenylsulfonyl-N'-triazinylureas |
| DE3927369A1 (de) * | 1989-08-19 | 1991-02-21 | Bayer Ag | Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe |
| US5064851A (en) * | 1990-07-24 | 1991-11-12 | Pfizer Inc. | 3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use |
| US5254589A (en) * | 1991-10-15 | 1993-10-19 | Warner-Lambert Company | Sulfonyl urea and carbamate ACAT inhibitors |
| DE4344957A1 (de) * | 1993-12-30 | 1995-07-06 | Hoechst Ag | Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Herstellungsverfahren und Verwendungsmöglichkeiten pharmazeutischer Präparate auf Basis dieser Verbindungen |
| CN1038679C (zh) * | 1994-12-07 | 1998-06-10 | 南开大学 | 磺酰脲类化合物及其除草用途 |
| HU226462B1 (en) * | 1995-02-17 | 2008-12-29 | Hoechst Ag | Substituted benzol-sulfonyl-ureas and -thioureas, process for producing them, pharmaceutical compositions containing them, and their use |
| AU6967198A (en) * | 1997-04-10 | 1998-10-30 | Eli Lilly And Company | Diarylsulfonylureas for use in treating secretory diarrhea |
-
1997
- 1997-12-29 SK SK982-99A patent/SK283679B6/sk unknown
- 1997-12-29 NZ NZ336248A patent/NZ336248A/xx unknown
- 1997-12-29 CN CN97181579A patent/CN1127479C/zh not_active Expired - Fee Related
- 1997-12-29 PT PT97947201T patent/PT964849E/pt unknown
- 1997-12-29 PL PL97335052A patent/PL335052A1/xx unknown
- 1997-12-29 HU HU0000567A patent/HUP0000567A3/hu unknown
- 1997-12-29 WO PCT/IB1997/001603 patent/WO1998032733A1/en active IP Right Grant
- 1997-12-29 EP EP97947201A patent/EP0964849B1/en not_active Expired - Lifetime
- 1997-12-29 AT AT02020749T patent/ATE270285T1/de not_active IP Right Cessation
- 1997-12-29 ID IDW990764A patent/ID22223A/id unknown
- 1997-12-29 IL IL13085597A patent/IL130855A0/xx unknown
- 1997-12-29 AT AT97947201T patent/ATE242208T1/de not_active IP Right Cessation
- 1997-12-29 CA CA002279186A patent/CA2279186C/en not_active Expired - Fee Related
- 1997-12-29 BR BR9714328A patent/BR9714328A/pt not_active Application Discontinuation
- 1997-12-29 EA EA199900603A patent/EA001803B1/ru not_active IP Right Cessation
- 1997-12-29 US US09/341,782 patent/US6166064A/en not_active Expired - Fee Related
- 1997-12-29 DK DK02020749T patent/DK1270565T3/da active
- 1997-12-29 YU YU33799A patent/YU33799A/sh unknown
- 1997-12-29 CZ CZ19992575A patent/CZ293173B6/cs not_active IP Right Cessation
- 1997-12-29 KR KR1019997006786A patent/KR100324058B1/ko not_active IP Right Cessation
- 1997-12-29 ES ES97947201T patent/ES2198598T3/es not_active Expired - Lifetime
- 1997-12-29 JP JP51868798A patent/JP3573757B2/ja not_active Expired - Fee Related
- 1997-12-29 DE DE69722663T patent/DE69722663T2/de not_active Expired - Fee Related
- 1997-12-29 DE DE69729762T patent/DE69729762T2/de not_active Expired - Fee Related
- 1997-12-29 TR TR1999/01816T patent/TR199901816T2/xx unknown
- 1997-12-29 AU AU52340/98A patent/AU723895B2/en not_active Ceased
- 1997-12-29 DK DK97947201T patent/DK0964849T3/da active
- 1997-12-29 ES ES02020749T patent/ES2222426T3/es not_active Expired - Lifetime
- 1997-12-29 PT PT02020749T patent/PT1270565E/pt unknown
-
1998
- 1998-01-16 PA PA19988444701A patent/PA8444701A1/es unknown
- 1998-01-20 UY UY24861A patent/UY24861A1/es unknown
- 1998-01-23 PE PE1998000051A patent/PE57898A1/es not_active Application Discontinuation
- 1998-01-26 TW TW087101087A patent/TW515788B/zh not_active IP Right Cessation
- 1998-01-27 DZ DZ980017A patent/DZ2407A1/xx active
- 1998-01-27 HR HR980045A patent/HRP980045B1/xx not_active IP Right Cessation
- 1998-01-27 AR ARP980100358A patent/AR011093A1/es not_active Application Discontinuation
- 1998-01-28 ZA ZA9800685A patent/ZA98685B/xx unknown
- 1998-01-28 MA MA24947A patent/MA26468A1/fr unknown
- 1998-01-28 TN TNTNSN98017A patent/TNSN98017A1/fr unknown
- 1998-01-29 CO CO98004326A patent/CO4920230A1/es unknown
- 1998-01-29 AP APAP/P/1998/001190A patent/AP929A/en active
-
1999
- 1999-06-29 IS IS5099A patent/IS5099A/is unknown
- 1999-07-22 BG BG103597A patent/BG103597A/bg unknown
- 1999-07-23 OA OA9900165A patent/OA11079A/en unknown
- 1999-07-28 NO NO19993658A patent/NO313279B1/no not_active IP Right Cessation
-
2000
- 2000-10-31 US US09/703,142 patent/US6433009B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0000567A2 (hu) | Szulfonil-karbamid-származékok és ezeket tartalmazó interleukin-1 aktivitás gátlására szolgáló gyógyászati készítmények | |
| HUP0000969A2 (hu) | Heterogyűrűs észterek és amidok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| HUP0101999A2 (hu) | 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása | |
| HUP0004529A2 (hu) | VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk | |
| HUP0402458A2 (hu) | Fokozott hatékonyságú kemokin receptor kötő heterociklusos vegyületek | |
| HUP0203312A2 (hu) | Farmakológiailag hatékony szulfonamidszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| AU8794291A (en) | New oxazolopyridine derivatives, processes for preparing these and pharmaceutical compositions containing them | |
| HUP0100669A2 (hu) | Szerin proteázokat gátló peptidszármazékok és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények | |
| DK0580502T3 (da) | 3-(hydroxybenzylidenyl)-indolin-2-oner og farmaceutiske sammensætninger indeholdende disse | |
| MX9801716A (es) | Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina. | |
| HUP0004531A2 (hu) | VLA-4 által mediált leukocita adhéziót gátló 4-aminofenilalanin-vegyületek, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk | |
| HUP0004259A2 (hu) | VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények | |
| HUP0001285A2 (hu) | Proteáz inhibitor hatású pirrolidinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| IL86381A0 (en) | Oxetanocins and pharmaceutical compositions containing the same | |
| BR8902929A (pt) | Artigo vendavel | |
| ATE48001T1 (de) | Cephemverbindungen, verfahren zu ihrer herstellung und ihre pharmazeutischen praeparate. | |
| HUT70548A (en) | Oxazolidone derivatives, process for producing them and pharmaceutical compositions containing them | |
| ES2103440T3 (es) | Nuevas amidas y sulfonamidas naftalenicas, procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
| ATE84035T1 (de) | Antivirale tetrahydroimidazo(1,4)benzodiazepin-2- one. | |
| HUP0301553A2 (hu) | Gyógyászati készítmények és alkalmazásuk neurológiai rendellenességek kezelésére | |
| HUP0103166A2 (hu) | Karbamát- és karbamidtartalmú készítmények, és neurotróf alkalmazásuk | |
| IT1216104B (it) | Peptidi ad attivita' farmaceutica. | |
| DK0420224T3 (da) | Anthihepatopatisk middel | |
| ES8707951A1 (es) | Derivados de tetrazol | |
| AU668398B2 (en) | New aminoalkylchromones, processes for the preparation thereof, and pharmaceutical compositions containing them |